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Summary
Background: Increased mitogen-activated protein kinase
(MAPK) signaling, small GTPase activation, cytoskeletal rear-
rangements, and the directed targeting of proteases to sites
of extracellular matrix degradation all accompany the process
of tumor cell invasion. Several studies have implicated the
small GTP-binding protein ARF6 in tumor cell invasion,
although the molecular basis by which ARF6 facilitates this
process is unclear.
Results: We show that the ARF6 GTP/GDP cycle regulates the
release of protease-loaded plasma membrane-derived micro-
vesicles from tumor cells into the surrounding environment.
To enable microvesicle shedding, ARF6-GTP-dependent
activation of phospholipase D promotes the recruitment of
the extracellular signal-regulated kinase (ERK) to the plasma
membrane where, in turn, ERK phosphorylates and activates
myosin light-chain kinase (MLCK). MLCK-mediated MLC
phosphorylation is required for microvesicle release. Inhibition
of ARF6 activation is accompanied by PKC-mediated phos-
phorylation of MLC, which blocks microvesicle shedding.
Protein cargo appears to be selectively sorted into microve-
sicles, and adhesion to the extracellular matrix (ECM) is facili-
tated by microvesicle-associated integrin receptors.
Conclusions: Microvesicle shedding in tumor cells occurs via
an actomyosin-based membrane abscission mechanism that
is regulated by nucleotide cycling on ARF6. Microvesicle shed-
ding appears to release selected cellular components, particu-
larly those involved in cell adhesion and motility, into the
surrounding environment. These findings suggest that ARF6
activation and the proteolytic activities of microvesicles, both
of which are thought to correlate directly with tumor progres-
sion, could potentially serve as biomarkers for disease.
Introduction
Metastasis, a life-threatening hallmark of cancer, occurs when
cells detach from the primary tumor and ‘‘invade’’ surrounding
tissues to reach distal locations [1]. Growth factor-induced
signaling, cytoskeletal rearrangements mediated by the Rho-
family GTPases, and alterations to adhesive and migratory
potential of cells all accompany the process of cell invasion
[2]. Furthermore, proteases from all four classes (serine,
cysteine, aspartic, and metalloproteases) have been impli-
cated in extracellular matrix (ECM) degradation, and their
expression, activation, and secretion are vital for tumor cell
invasion [3].
*Correspondence: cdsouzas@nd.eduOver the past few years, ARF6, of the ARF family of small
GTP-binding proteins, has emerged as an important signaling
molecule and has been shown to regulate membrane traf-
ficking and actin cytoskeleton remodeling, both of which can
impinge on the acquisition of migratory and/or invasive poten-
tial (reviewed in [4]). Recent studies utilizing in vitro cell inva-
sion assays have indicated that in invasive melanoma, glioma,
and breast cancer cell lines, the ARF6 GTP/GDP cycle can
regulate invasive potential [4]. Cellular depletion of ARF6 by
small interfering RNA (siRNA) or inhibition of ARF6 activation
by expression of a dominant-negative ARF6 mutant attenuates
tumor cell invasion in vitro. Recent studies in animal models
have also revealed a vital role for ARF6 activation in melanoma
and glioma cell invasion [5, 6]. Moreover, screening of various
breast tumor cell lines reveals a direct correlation between
ARF6 protein expression and invasive capacity [7]. Finally,
the ARF6 exchange factor GEP100 is expressed in 70% of
primary breast ductal carcinomas and is preferentially coex-
pressed with EGFR in malignant tumors [8].
What might be the cellular basis by which ARF6 promotes
cell invasion? First, ARF6 has been implicated in regulation
of invadopodia turnover [4]. Second, via its effects on
membrane traffic and remodeling, ARF6 could regulate
protease secretion. The current study focuses on the role of
ARF6 in protease release. We show that, via its effects on
phospholipid metabolism and extracellular signal-regulated
kinase (ERK) activation, ARF6 regulates protease release by
modulating the shedding of plasma membrane-derived micro-
vesicles into the surrounding environment. Vesicle shedding
by the outward fission of membrane vesicles from the cell
surface is a selective process that occurs in a spectrum of
normal and, more frequently, tumor cells, both in vivo and
in vitro [9]. These released microvesicles (also referred to as
microparticles, particles, and ectosomes) have been widely
detected in various biological fluids including peripheral blood
and ascitic fluids; their composition depends on the cells from
which they originate [10, 11]. They are thought to facilitate cell
invasion, evasion of the immune response, bone mineraliza-
tion, and even tumor cell intravasation by reducing cell size
[12]. Here we provide structural and biochemical characteriza-
tion of ARF6-positive microvesicles shed by tumor cells. We
also show that protease cargo contained within the microve-
sicles is functionally robust and promotes matrix degradation.
Finally, we delineate the pathway by which ARF6 maneuvers
the actomyosin machinery to facilitate shedding of microve-
sicles from the tumor cell surface. These findings are signifi-
cant particularly in light of reports demonstrating that proteo-
lytic activities of microvesicles shed by tumor cells correlate
directly with malignancy and invasiveness [13, 14].
Results
Phenotypic Variations of LOXARF6-GDP
and LOXARF6-GTP Cell Lines
To investigate mechanisms by which ARF6 promotes cell inva-
sion, we made use of LOXARF6-GTP and LOXARF6-GDP cell lines
that stably express either a HA-tagged, GTPase-deficient
mutant of ARF6, ARF6-Q67L, or the dominant-negative ARF6
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1876Figure 1. Phenotypic Variations Observed in LOXARF6-GDP and LOXARF6-GTP Mutant Lines
(A) Parental LOX, LOXARF6-GTP, and LOXARF6-GDP cells lines were fixed and stained with rhodamine-phalloidin to visualize actin filament distribution or
b1-integrin antibody, as indicated. Panels show the range of phenotypes in the LOX cell lines. Scale bar represents 10 mm.
(B) Parental LOX, LOXARF6-GTP, and LOXARF6-GDP cells in culture at low confluency were imaged via phase-contrast microscopy. Arrows point to shed
vesicles in the growth media of LOX and LOXARF6-GTP cells. Scale bar represents 10 mm.
(C) Vesicles released into the growth media from 2.23 106 LOX, LOXARF6-GTP, and LOXARF6-GDP cells were isolated and probed for ARF6 and b1-integrin by
western blotting (left), or protein was quantitated (right). The average of three separate experiments is shown with standard error bars. Cell lysates were
probed for ARF6 and a-tubulin by western blotting. Lower- and higher-molecular-weight ARF6 bands in LOXARF6 cells correspond to endogenous and
HA-tagged exogenous ARF6, respectively.
(D) LOXARF6-GTP and LOXARF6-GDP cells were plated on FITC-gelatin-coated coverslips and allowed to ‘‘invade.’’ The cells were fixed and stained for cortactin
(blue) and actin (red) (top) or b1-integrin (red) (middle and bottom). Arrows point to invadopodia; arrowheads indicate shed vesicles. Note the arborization
phenotype of LOXARF6-GTP cells when the underlying gelatin is relatively thick (middle). Scale bar represents 10 mm.
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1877mutant, ARF6-T27N, respectively. The most striking phenotype
observed upon microscopic examination of LOXARF6-GDP cells
was the presence of vesicle-like bulbous structures that deco-
rated the cell surface (Figures 1A and 1B). These structures
were also seen on the surfaces of LOX and LOXARF6-GTP cell
lines (Figures 1A and 1B), although they were less readily
obvious. Instead, in the latter two cell lines, vesicles were
released into the growth medium (Figure 1B). The lack of vesi-
cles in the growth media of LOXARF6-GDP cells suggests that
ARF6 activation is likely required for their release. When
collected by low-speed centrifugation of the growth media
and examined for total protein or probed for ARF6 expression,
vesicles shed from LOXARF6-GTP cells exhibited significantly
more protein and ARF6, indicative of increased shedding
from these cells, relative to the parental cell line (Figure 1C).
Furthermore, mutant ARF6-GDP was not present on shed
vesicles.
The release of vesicles was not as apparent in earlier inves-
tigations when LOX cells were seeded on gelatin matrix [15],
presumably because they were released into the matrix at
the sites of cell invasion. In addition, their detection could
have been hampered as a result of low efficiency of transient
transfection used in the previous study. In this study, however,
upon careful examination of LOXARF6-GTP cells on gelatin-
coated coverslips, we were able to detect the presence of
vesicles in the matrix on the cell surface (Figure 1D). Further-
more, as shown in Figure 1D, upper panel, these vesicular
structures appear to be distinct from cortactin-positive inva-
dopodia that extend into the gelatin matrix. Vesicles do not
contain cortactin, although they label forb1-integrin (Figure 1D;
see also below), which is also present in invadopodia [16].
Quantitation of cortactin label in vesicles relative to invadopo-
dia is shown in Figure S1 available online. Some cells exhibit
expansive membrane arbors decorated with microvesicles
(Figure 1D, middle panel). Cells had a tendency to adopt this
arborization phenotype, suggestive of horizontal movement
when the underlying gelatin is relatively thick (R5 mm). It is
possible that cells form invadopodia at the adherent face
initially and that when they invade into ‘‘substantial’’ matrix
and move laterally, this arbor phenotype takes effect. In
contrast, LOXARF6-GDP cells appear bulbous when plated on
gelatin, largely because of vesicles studded at the cell surface
and little to no matrix degradation underneath the cells (Fig-
ure 1D, lower panel). As reported previously, invadopodia
protrusions at the adherent surface were not observed upon
expression of the dominant-negative ARF6 mutant [15]. Thus,
ARF6 activation is coupled to two apparently distinct cellular
processes linked to matrix invasion, invadopodia formation
and the release of surface vesicles into the surrounding envi-
ronment. In this study, we focus on mechanisms underlying
ARF6-regulated vesicle shedding from the tumor cell surface.
Morphological examination of LOXARF6-GTP and LOXARF6-GDP
cell lines via electron microscopy (EM) suggested that vesicles
at the surface of cells are heterogeneous in size (300–900 nm)
(Figure 1E). EM-based investigations also indicated that cells
display no signs of nuclear fragmentation or apoptosis. All of
the above suggests that the ARF6 GTPase cycle regulates
the release of a heterogeneous population of vesicles from
tumor cells into the surrounding environment.We also examined vesicle shedding in other tumor cell lines:
SW480, a colon carcinoma cell line; PC3, a prostate adenocar-
cinoma cell line; and MDA-MB-231, an invasive breast tumor
cell line. Gross morphological examination by phase-contrast
microscopy showed that shed vesicles were present in the
growth media of all aforementioned cell lines (data not shown).
Analysis of shed vesicles collected from the growth media by
immunoblotting revealed the presence of endogenous ARF6
on isolated vesicles (Figure 1F). Furthermore, dominant inhibi-
tion of ARF6 function by expression of ARF6-T27N in these
tumor cell lines prevented vesicle release (data with SW480
cell line is shown in Figure S2).
ARF6-GTP Facilitates the Release of Plasma
Membrane-Derived ‘‘Microvesicles’’ into
the Surrounding Environment
There is accruing evidence for the existence of unconventional
secretory mechanisms, such as the release of exosomes and
microvesicles that do not utilize the classical signal-peptide
secretory transport pathway. Exosomes are internal vesicles
of multivesicular bodies and/or late endosomes that are
released upon exocytosis [17]. Morphological characterization
of ARF6-regulated shed vesicles suggests that they are
‘‘microvesicles,’’ and henceforth they are referred to as such.
Isolated ARF6-positive vesicles pellet by centrifugation at
w10,000 3 g, unlike exosomes, which sediment by centrifu-
gation at w100,000 3 g (Figure 2A). Figure 2A shows that
ARF6-positive vesicles are not present in the 100,0003 g frac-
tion. Ultrastructural analyses of whole-mount preparations of
the 10,000 and 100,000 3 g fractions confirmed the heteroge-
neity of the 10,000 3 g microvesicles relative to the more
uniform 50–70 nm vesicles characteristic of exosomes in the
100,000 3 g fraction (Figure 2B).
Studies have shown that phosphatidylserine (PS) external-
ization accompanies shedding of plasma membrane-derived
microvesicles [11]. Indeed, we found externalization of PS on
the surface of microvesicles based on reactivity with annexin
V, a high-affinity PS-binding protein. This was particularly
evident in LOXARF6-GDP cells where microvesicles stud the cell
surface (Figure 2C). We also noted that these microvesicles
are not apoptotic bodies. As stated above, expression of
ARF6 mutants in LOX cells does not induce morphological
changes, such as condensed chromatin and pyknotic nuclei,
or label for cleaved caspase-3. On the other hand, when treated
with okadaic acid, a known inducer for apoptosis, a higher
proportion of cells label for cleaved caspase-3 (Figure 2D).
Thus, ARF6 activation facilitates the release of microvesicles.
Shed Microvesicles Contain Proteases and Facilitate
ECM Degradation
Previous reports have shown that microvesicles shed by
breast carcinoma and ovarian cancer cell lines contain prote-
ases like MMP-2 and MMP-9 [18]. We found that ARF6-posi-
tive microvesicles from the 10,000 3 g fraction contained
high- and low-molecular-weight gelatinases, as indicated by
gelatin zymography (Figure 3A) and MT1MMP (Figure 4B). Of
note, MT1MMP silencing significantly decreased the basal
invasiveness in parental LOX cells (unpublished data). More-
over, shed vesicles, when seeded on FITC-gelatin, were(E) LOXARF6-GTP and LOXARF6-GDP cells lines were analyzed by electron microscopy. Image in top panel shows heterogeneous vesicular structures near the
surface of LOXARF6-GTP cells. Lower panel shows vesicular structures that appear to stud the surface of LOXARF6-GDP cells. Scale bar represents 1000 nm.
(F) Vesicles released into the growth media from an equivalent number (1.53 106 cells) of indicated tumor cell lines in culture were isolated and probed for
ARF6 by western blotting.
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around microvesicle membranes (Figure 3B).
It has been proposed that b1-integrins facilitate interaction
of shed microvesicles with the ECM and that vesicle contents
are released after microvesicle burst induced by acidic pH
characteristic of the tumor environment [19]. We found that
addition of inactivating b1-integrin antibody AIIB2 to isolated
microvesicles (Figure 3B) or LOX cells (data not shown)
blocked adhesion and matrix degradation, suggesting that
protein topology in the microvesicle membrane is still main-
tained and that integrin receptor association with matrix is
important for microvesicle-mediated matrix degradation.
AIIB2 also labels the extracellular surface of cells and shed
microvesicles (Figure 3C). Thus, although proteases at the
invadopodia surface facilitate local pericellular proteolysis,
microvesicle release could provide a mechanism for rapid
and directed proteolysis at distal sites creating paths of less
resistance.
Selective Sorting of Cargo into Cell Surface Microvesicles
Besides proteases, microvesicles have been shown to be
selectively enriched in b1-integrin receptors and major histo-
compatibility complex (MHC) class I molecules. Both MHC
class I molecules and integrin receptors traffic to and from the
plasma membrane via ARF6-regulated endosomal compart-
ments [20]. Figure 3D shows labeling for MHC class I in
LOXARF6-GDP cells in the perinuclear compartments and at the
cell surface, but largely at the cell surface in LOXARF6-GTP cells.
Figure 2. ARF6-Positive Microvesicles Are
Distinct from Exosomes
(A) Microvesicles shed by parental LOX and
LOXARF6-GTP cell lines were fractionated as
described in Experimental Procedures, and
equivalent protein from each fraction was probed
for ARF6. Endogenous ARF6 and HA-tagged
mutant ARF6 are enriched only in the 10,000 3 g
fraction.
(B) Fractionated vesicle populations isolated
from LOXARF6-GTP cells were analyzed by whole-
mount electron microscopy. Microvesicles iso-
lated in the 10,000 3 g fraction are larger (300–
900 nm) and heterogeneous relative to the more
uniform 50–70 nm vesicles in the 100,000 3 g
fraction typical of exosomes. Scale bar repre-
sents 500 nm.
(C) The surface of LOXARF6-GDP cells was labeled
with annexin V (green) to demarcate areas of
phosphatidylserine (PS) externalization and b1-
integrin (red), a surface marker. Top panel shows
annexin V labeling only. When the green signal is
dampened, enrichment of annexin V labeling at
sites of vesicle shedding is observed. Scale bar
represents 10 mm.
(D) Parental LOX, LOXARF6-GDP, and LOXARF6-GTP
cell lines with or without treatment with 50 nM
okadaic acid for 3 hr were fixed and labeled for
cleaved caspase-3 (green) and stained with TO-
PRO-3 iodide, a nuclear stain (blue). Scale bar
represents 10 mm.
Western blotting analysis of shed vesi-
cles revealed that along with endoge-
nous ARF6, MHC-I, b1-integrin, VAMP3,
and MT1MMP were also present in
microvesicles (Figure 3E). Of note, pro-
cessed forms of MT1MMP are present
in the microvesicles. However, microvesicles were devoid of
transferrin receptors, which localize to endosomes and the
cell surface; Rab8 and VAMP7, which regulate the targeting of
MT1MMP to the cell surface; and cortactin and Tks5, which
are present in invadopodia. Thus, cargo trafficked via recycling
endosomes to the cell surface appears to be selectively sorted
into these surface microvesicles.
ARF6-GTP-Induced Microvesicle Shedding Requires ERK
ARF6-enhanced melanoma cell invasion is dependent on the
activation of ERK [15]. Moreover, the ARF6 GTPase cycle regu-
lates ERK activation [15, 21, 22] downstream of c-Raf [23].
Therefore, we investigated whether ARF6-GTP-induced micro-
vesicle shedding is also dependent on ERK signaling. Treat-
ment of LOX and LOXARF6-GTP cells with U0126, an inhibitor of
MEK, the kinase immediately upstream of ERK, resulted in
significant inhibition of basal as well as ARF6-GTP-enhanced
microvesicle shedding (Figure 4A). Upon MEK inhibition, both
parental LOX and LOXARF6-GTP accumulated microvesicles at
the cell surface that resembled the LOXARF6-GDP phenotype
(Figure 4B). Similarly, MEK inhibition also blocked microvesicle
shedding from PC3 and SW480 cell lines (Figure S3). Thus,
ARF6-regulated microvesicle shedding requires ERK.
Consistent with earlier findings in HeLa cells [21], we found
that ERK localizes to the cytoplasm in LOXARF6-GDP cells (Fig-
ure 4C). In contrast, membrane-associated ERK is predomi-
nantly at the cell surface in LOX and LOXARF6-GTP cells. This
becomes further evident in subcellular fractionation studies,
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cantly more in the membrane fraction of LOXARF6-GTP cells
(Figure 4D). Thus, ARF6 activation likely enhances ERK redis-
tribution to the plasma membrane, which in turn facilitates its
phosphorylation and microvesicle release.
ARF6-Regulated ERK Activation Requires
Phospholipase D
Studies have shown that ARF6 simulates phospholipase D
(PLD) activity [4]. Further, PLD has been shown to facilitate
ERK activation. Here we tested the hypothesis that ARF6-
regulated PLD activity is required for ERK activation. First we
examined phospho-ERK levels upon PLD inactivation. We
found that expression of ARF6-N48I, an ARF6 mutant defec-
tive in PLD activation, inhibits ERK activation (Figure 5A) and
microvesicle shedding (Figure 5B). Phosphatidic acid (PA)
levels were significantly decreased in ARF6-N48I-expressing
cells (Figure 5C), and this decrease was accompanied by
ERK localization to intracellular cytoplasmic structures (Fig-
ure S4). Next we used primary alcohols to inhibit PLD, which
results in the formation of phosphatidyl alcohol at the expense
of phosphatidic acid by replacing water. We found that
Figure 3. Shed Microvesicles Contain Functional Proteases and
Other Selective Membrane Proteins
(A) Microvesicles shed from an equal number of parental LOX and
LOXARF6-GTP cells were isolated, and microvesicle lysates were
analyzed by gelatin zymography. Cell lysates were probed for
a-tubulin expression. High and low molecular weight gelatinases
are present in microvesicle lysates.
(B) Shed microvesicles isolated from the growth medium were
gently overlaid on FITC-gelatin-coated glass coverslips for 8 hr in
the absence or presence of AIIB2, the anti-b1-integrin blocking anti-
body. Coverslips were stained for actin (red) to identify microve-
sicles (see arrows). The dark spots on the FITC-gelatin are indicative
of degradation underneath isolated microvesicles (left). Adhesion of
microvesicles to the matrix was reduced to less than 10% in the
presence of AIIB2 antibody. Image intentionally shows residual
labeling (right). Scale bar represents 10 mm.
(C) b1-integrin antibody was used to label the extracellular surface of
nonpermeabilized LOXARF6-GTP cells. Scale bar represents 10 mm.
(D) Parental LOX, LOXARF6-GDP, and LOXARF6-GTP cells were fixed and
stained for actin (green) and endogenous major histocompatibility
complex (MHC)-1 (red). Scale bar represents 10 mm.
(E) Lysates of LOXARF6-GTP cells or of shed microvesicles were
analyzed for indicated endogenous proteins or transfected proteins
(EGFP-VAMP3 or EGFP-VAMP7) by western blotting.
treatment of cells with 1-butanol also inhibits ERK acti-
vation (data not shown) and microvesicle shedding (Fig-
ure 5D). Thus, PLD activation is upstream of ERK activa-
tion and is essential for ARF6-regulated microvesicle
shedding.
Nextwe investigatedwhetherwecould rescue theshed-
ding of microvesicles in LOXARF6-GDP cells by restoring
phospho-ERK levels or by stimulating PLD activity by
pathways independent of ARF6. Treatment with propran-
olol, a PA phosphohydrolase inhibitor [24], restored phos-
pho-ERK levels in LOXARF6-GDP cells (Figure 5E) and
induced microvesicle shedding in LOXARF6-GDP cells (Fig-
ure 5F). Unlike propranolol, another G protein-coupled
receptor antagonist, atenolol, did not have any effect on
phospho-ERK levels or microvesicle release (Figures 5E
and 5F). These data corroborate the importance of
PLD and ERK activation in regulating microvesicle shed-
ding. Finally, we determined the effect of 1-butanol on
microvesicle shedding induced by expression of constitutively
activated MEK. Activated MEK increases microvesicle shedding
more than 12-fold compared to the parental LOX cells; however,
1-butanol had little to no effect on microvesicle shedding, con-
firming that ERK lies downstream of PLD activation (data not
shown).
ERK Facilitates Microvesicle Shedding by Phosphorylating
Myosin Light Chain
Treatment of LOX cells with blebbistatin, a small-molecule
inhibitor of myosin II activity, or with latrunculin A, an actin-
binding toxin that inhibits actin polymerization, profoundly
affected the microvesicle release. In the presence of blebbis-
tatin, microvesicles did not form (Figure 6A). Eighty-five to
ninety percent of latrunculin A-treated cells exhibited clus-
tered microvesicles at the cell surface (Figure 6A). Accord-
ingly, latrunculin A treatment also inhibited the release of mi-
crovesicles from both parental LOX and LOXARF6-GTP cells
(Figure 6B). Thus, vesicle shedding is likely mediated via an
actomyosin-dependent mechanism. Myosin light-chain kinase
(MLCK), a Ca2+/calmodulin-dependent kinase, phosphory-
lates myosin II light chain (MLC) to promote contraction of
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(A) Parental LOX and LOXARF6-GTP lines were treated with 30 mM U0126, and microvesicles shed into the media were isolated and quantitated for protein.
Data from five independent experiments are plotted. Standard error bars are shown.
(B) Parental LOX and LOXARF6-GTP cell lines with or without treatment with U0126 were fixed and stained for actin. Arrows point to the microvesicles at the cell
surface. Scale bar represents 10 mm.
(C) GFP- ERK (green) and Myc-tagged ARF6 mutants as indicated (red) were transiently transfected into LOX, fixed, and stained with anti-Myc. There is
overlap of GFP-ERK and ARF6-GDP in endosomes, and a significant ERK pool is at the cell surface with ARF6-GTP expression. Scale bar represents 10 mm.
(D) Parental LOX, LOXARF6-GDP, and LOXARF6-GTP cells were subjected to subcellular fractionation, and the amount of endogenous phospho-ERK and total
ERK in the membrane and cytosolic fractions was analyzed by immunoblotting.the actin-based cytoskeleton [25]. ERK has been shown to
phosphorylate MLCK, which in turn phosphorylates MLC at
Thr18/Ser19 and thereby stimulates MLC activity [26, 27]. We
tested the hypothesis that ARF6-GTP-induced ERK activation
at sites of vesicle release leads to localized activation of
MLCK, which in turn stimulates serine phosphorylation of MLC
to allow force generation required for microvesicle fission. In
support of this contention, immunofluorescence labeling of
LOX tumor cells revealed that phospho-MLC localizes to the
‘‘necks’’ of microvesicles at the cell surface (Figure 6C).
We examined phosphorylation of MLC in parental LOX and
LOX mutant lines by western blotting. As shown in Fig-
ure 6D, levels of phospho-MLC are significantly increased in
LOXARF6-GTP cells compared to parental LOX cells. Treatment
of parental LOX and LOXARF6-GTP cells with ML-7, an MLCK
inhibitor, blocks MLC phosphorylation as well as microvesicle
shedding (Figure S5). Taken together, these data show that
ARF6 facilitates microvesicle fission via a mechanism that
involves ERK-dependent MLC phosphorylation.
As seen in Figure 6D, and contrary to our expectations,
no decrease in phospho-MLC levels was observed in
LOXARF6-GDP cells, and in fact they were slightly higher than
basal levels. A possible explanation for this observation is
that the phosphorylation of MLC in LOXARF6-GDP cells is ‘‘inhib-
itory’’ and independent of ERK. To investigate this further, wecompared the levels of phospho-MLC in the presence and
absence of U0126 in parental LOX and LOX mutant lines.
As seen in Figure 6E, inhibition of phospho-MLC was evident
in the presence of MEK inhibitor in parental LOX and in
LOXARF6-GTP cells, but there was no inhibition in phospho-
MLC levels in LOXARF6-GDP cells. Also, treatment with ML7 had
little to no effect on MLC phosphorylation in LOXARF6-GDP cells
(Figure S5). This further confirms that the phosphorylation of
MLC in LOXARF6-GDP cells is not mediated by ERK.
We examined alternative pathways such as the activation of
PKC or p38 [28, 29] for MLC phosphorylation in LOXARF6-GDP
cells. To distinguish between PKC- and p38-mediated phos-
phorylation of MLC, LOXARF6-GDP cells were treated with
SB203580, a p38 inhibitor, or Go6976, a PKC inhibitor. We
found that phospho-MLC levels were decreased specifically
upon PKC inhibition (Figure 6F). Thus, MLC phosphorylation
in LOXARF6-GDP occurs via PKC and is independent of phos-
pho-ERK. We also noted that MLC phosphorylation is indepen-
dent of PKC in parental LOX and in LOXARF6-GTP cells, because
no decrease in phospho-MLC levels was observed in the pres-
ence of PKC inhibitor (Figure S4). Thus, in LOXARF6-GDP cells,
MLC is phosphorylated by PKC, which is inhibitory, whereas
in LOXARF6-GTP cells, MLC phosphorylation is regulated up-
stream by ERK, a step that promotes MLC-regulated contrac-
tion and, in turn, microvesicle fission (see Figure 7). Pertinent
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has been documented to decrease MLC activity. In this regard,
slow stretch of the canine basilar artery is accompanied by the
triphosphorylation of myosin light chain (MLC20) at Thr9, Thr18,
and Ser19, which results in the inhibition of myogenic contrac-
tion and thereby muscle relaxation [30]. In sum, ARF6-GTP
facilitates microvesicle fission via a mechanism that involves
ERK-dependent MLC phosphorylation, and ARF6-GDP has
the opposite effect via PKC-induced phosphorylation of MLC.
Discussion
Microvesicle-mediated release of proteases is an important
but understudied area of tumor cell biology. Our studies
Figure 5. ARF6-Induced ERK Activation
Requires Phospholipase D
(A) Lysates of LOX cells transiently transfected
with HA-tagged ARF6-N48I mutant were probed
for phospho-ERK and total ERK by western blot-
ting. The data are representative of three sepa-
rate experiments. Band intensities were quanti-
fied by densitometry, and the ratio of phospho-
ERK to total ERK is shown.
(B) Microvesicles released into the media by
parental LOX and LOX cells transfected with
ARF6-N48I were isolated by differential centrifu-
gation and quantitated for the protein content.
The average of four separate experiments with
standard error bars is shown. Microvesicles in
the growth media of cells expressing ARF6-
N48I are lower relative to untransfected controls.
(C) LOX cells were cotransfected with expression
plasmids encoding ARF6-N48I and GFP-Spo20-
PABD, a fluorescent phosphatidic acid (PA)
probe. PA levels are decreased upon expression
of the ARF6 mutant. Scale bar represents 10 mm.
(D) LOX cells were treated with 0.3% t-butanol or
1-butanol for 30 min, fixed, and stained for actin
to visualize surface-associated microvesicles.
For each experimental condition, cells that
showed eight or moremicrovesicles at the surface
were scored, and the percent inhibition of vesicle
shedding was determined. Two hundred fifty cells
were observed for each experiment, and the data
from four independent experiments are plotted.
Standard error bars are shown.
(E) Lysates of LOXARF6-GDP cells treated with
propranolol (0.1 mM) and atenolol (10 mM) were
probed for phospho-ERK and total ERK. Band
intensities were quantified by densitometry. The
average of three independent experiments is
plotted, and standard error bars are shown.
(F) LOXARF6-GDP cells treated with propranolol or
atenolol were visualized, and cells with microve-
sicles at the cell surface were scored as described
above. Propranolol treatment of LOXARF6-GDP
cells restored vesicle shedding.
demonstrate that ARF6 has a critical
role in regulating the shedding of micro-
vesicles containing functional prote-
ases. Microvesicle release is dependent
on PLD activity, which in turn leads to
the activation of ERK. ERK phosphory-
lates and activates MLCK, a known sub-
strate for phospho-ERK. MLCK, in turn,
phosphorylates and activates MLC. This
would allow actomyosin-based contraction at the necks of
microvesicles, facilitating their release into the extracellular
space.
There is mounting evidence that the release of microvesicles
serves to facilitate ECM degradation. Most striking in this
regard is the reported presence of protease-loaded membrane
microvesicles with invasive properties in malignant ovarian
ascites derived from women with stage I–IV ovarian cancer
[14]. This study also showed that late-stage ascites had signif-
icantly more microvesicles than those in early-stage disease,
although the invasive ability of the microvesicles was about
the same irrespective of the disease stage. These studies
assert the physiological relevance and importance of the
data described here. Indeed, we show that processed forms
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(A) LOX cells were treated with either 100 mM blebbistatin or 2 mM latrunculin A, fixed, and stained for actin to visualize surface-associated microvesicles.
Scale bar represents 10 mm.
(B) Parental LOX, LOXARF6-GTP, and LOXARF6-GDP cells in culture were incubated with fresh media containing 2 mM latrunculin A for 45 min. Microvesicles
released were isolated and quantitated for protein. The average of three independent experiments with standard error bars for each experimental condition
is shown.
(C) LOX cells were fixed and stained for endogenous phospho-myosin light chain (MLC) (green) and actin (red). Note the localization of phospho-MLC at the
‘‘necks’’ of surface microvesicles. Scale bar represents 5 mm.
(D) Cell lysates of LOX, LOXARF6-GTP, and LOXARF6-GDP cells lines were analyzed for endogenous phospho-MLC by western blotting. a-tubulin expression
was also assessed as an indicator for equal loading. Band density was measured by densitometric scanning.
(E) Lysates of LOX cells treated with U0126 (30 mM) were analyzed for endogenous phospho-MLC, phospho-ERK, total ERK, and a-tubulin by western
blotting. Additional lanes on the immunoblot between lanes 2 and 3 were spliced out. Band density was measured by densitometric scanning.
(F) LOXARF6-GDP cells were treated with various inhibitors (Go6976 [PKC inhibitor, 10 mM], ML-7 [myosin light-chain kinase (MLCK) inhibitor, 10 mM], U0126
[MEK inhibitor, 30 mM], and SB203580 [p38 inhibitor, 10 mM]) for 2 hr at 37C. Cell lysates were probed for phospho-MLC, phospho-ERK, and a-tubulin by
western blotting.
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present in the microvesicles.
Besides facilitating ECM degradation, microvesicles have
also been shown to promote the horizontal propagation of
oncogenes among subsets of cancer cells [31]. Microvesicles
shed from glioblastoma cells have been shown to contain
microRNAs in addition to angiogenic factors [32]. Studies
also suggest that microvesicles enable the escape of tumors
from immune surveillance, thus promoting tumor cell survival
[33]. Consistent with these findings, we observed that MHC
class I is contained within microvesicles. How cargo is directed
to surface-associated vesicles will require further investiga-
tion, although it appears that cargo contained and trafficked
via ARF6-regulated endosomal pathways, e.g., MHC class I,
b1-integrin receptors, and VAMP3 [4], are delivered to the
microvesicles. Microvesicles are devoid of VAMP7 and Rab8,
both of which have been implicated in MT1MMP delivery to
the cell surface [34, 35], and also of transferrin receptors, which
also traffic through the ARF6 compartment in some cell types
(reviewed in [4]). Thus, cargo appears to be selectively sorted
into microvesicles at the cell surface. We suggest that vesicle
shedding occurs at specific sites on the plasma membrane
and is designed to release selected cellular components into
the surrounding environment, particularly those involved in
cell-matrix interactions and matrix degradation. Rab8- and
VAMP7-dependent MT1MMP delivery to the cell surface likely
facilitates pericellular proteolysis.
This study also supports the view that microvesicle release
is accompanied by localized lipid scrambling and that
vesicle-mediated proteolysis requires the binding of integrin
receptors to the ECM [36]. Localized lipid scrambling with
PS externalization has also been shown to occur in other non-
apoptotic processes such as myotube formation [37] and
rapid modulation of the activity of signaling proteins at the
surface of nonapoptotic lymphocytes [38].
Figure 7. Working Model for ARF6-Mediated Regulation of Cell Invasion
(A) Activated ARF6 facilitates tumor cell invasion by promoting invadopodia
formation and microvesicle shedding. The formation of invadopodia and
microvesicle release requires ARF6 and ERK.
(B) The signaling pathway downstream of ARF6-regulated ERK activation
required for microvesicle shedding is shown. ARF6-regulated ERK localiza-
tion to and its activation at plasma membrane require phospholipase
D (PLD). ERK-induced phosphorylation of MLCK in turn promotes MLC
phosphorylation required for actomyosin-based membrane fission, leading
to microvesicle release.Pharmacological inhibition of actin polymerization and
myosin function prevents microvesicle release, suggesting
that outward fission likely occurs via an actomyosin-based
process. We show that ARF6-dependent activation of ERK
promotes MLCK phosphorylation and subsequent MLC phos-
phorylation, thereby facilitating actomyosin-based contrac-
tion at vesicle necks, leading to microvesicle release. The intri-
cate rigor of this regulation is manifest in the fact that when
ARF6 activation is blocked, not only does ERK activation
and ERK-regulated MLCK phosphorylation not ensue, but
PKC-mediated phosphorylation and inactivation of MLC also
occurs as a consequence (Figure 7). All of these observations
support earlier findings that ARF6-induced ERK activation has
a profound effect on tumor cell invasion. ARF6-induced ERK
activation is dependent on the accumulation of PA. PA could
facilitate ERK recruitment to the cell surface as described
above, but may also be required to modify the lipid environ-
ment to facilitate the recruitment of components of the ERK
cascade such as Raf to the plasma membrane as previously
documented [39, 40].
Invadopodia and microvesicles appear to be distinct struc-
tures. Cortactin, a bona fide component of invadopodia, is
absent in microvesicles. Although proteases at the invadopo-
dia surface might represent a mechanism for local pericellular
proteolysis at the leading/invading membrane edge, microve-
sicle release likely promotes more distant focal proteolysis
and creation of an invasion path. It is possible that some tumor
lines may exhibit both invasion mechanisms, whereas in
others one of these mechanisms may dominate. The formation
of invadopodia and release of microvesicles are both depen-
dent on ARF6-induced ERK activation (Figure 7).
The shedding of membrane microvesicles is not restricted to
pathological conditions and is also observed in normal physi-
ological conditions. For example, microvesicles secreted by
skeletal cells enable bone mineralization in vivo, whereas
microvesicles secreted by normal endothelial cells have
been implicated in angiogenesis [41]. Microvesicles have
also been shown to play a role in mRNA transfer in embryonic
stem cells and in viral packaging and delivery to the extracel-
lular environment [12, 36, 42]. Thus, in addition to providing
strategies for cancer therapeutics and diagnostics, knowledge
about the mechanism of microvesicle shedding may shed light
on other events requiring plasma membrane budding.
Experimental Procedures
Antibodies and Plasmids
The following antibodies were used in this study: anti-neutralizing b1-integ-
rin, AIIB2 (Developmental Studies Hybridoma Bank at the University of
Iowa), anti-Rab-8A and anti-Tsk5 (Santa Cruz Biotechnology), anti-MHC-
class I (AbD Serotec), anti-HA (Covance), anti-TfnR (Zymed), antibodies
against phospho-MLC, phospho-ERK, total ERK, cortactin, and cleaved
caspase-3 (Cell Signaling Technology), anti-a-tubulin antibody (Sigma-
Aldrich), and anti-GFP (Roche). The MT1MMP antibody was a gift from
M.C. Rio (Institut de Ge´ne´tique et de Biologie Mole´culaire et Cellulaire,
CNRS/INSERM/ULP, Illkirch, Strasbourg, France). GFP-ERK (Addgene
plasmid 14747) was from Addgene [43]. HA-tagged ARF6-N48I was kindly
provided by N. Vitale (Centre National de la Recherche Scientifique and Uni-
versite Louis Pasteur). Plasmids encoding GFP-VAMP3 and GFP-VAMP7
were a gift from T. Galli (Institut Jacques Monod, Paris).
Cell Culture and Microvesicle Isolation
LOX, LOXARF6-GTP, and LOXARF6-GDP cell lines were cultured as described
[5]. Cells were seeded in tissue culture flasks at 50% confluency. Media
was carefully removed from cells at w80% confluence and centrifuged
consecutively at 800 3 g for 10 min, 2,500 3 g for 15 min, and 10,000 3 g
for 30 min. Where indicated, this was followed by centrifugation of the
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1884supernatant at 100,000 3 g for 1 hr. Isolated microvesicles were washed in
phosphate-buffered saline (PBS) and lysed, and protein content was esti-
mated via the Bradford assay (Bio-Rad).
Gelatin Zymography
Microvesicles isolated from the growth media were lysed in RIPA buffer and
separated on SDS-PAGE gels containing gelatin to assess gelatinase
activity, as previously described [44].
In Vitro Degradation Assay
The gelatin degradation assay was as previously described [45]. Alterna-
tively, isolated microvesicles were seeded and incubated on gelatin-coated
coverslips for 6–8 hr.
Immunofluorescence Staining and Microscopy
Cultured cells and/or microvesicles plated on poly-L-lysine-coated or
gelatin-coated glass coverslips were fixed and processed as described
[5]. F-actin distribution was visualized by staining with rhodamine-phalloidin
(Molecular Probes). Labeling of the cell surface with FITC-annexin V was
performed with a kit from Beckman Coulter according to the manufacturer’s
protocol. Cells were fixed and, where indicated, the surface was labeled for
b1-integrin (without permeabilization) and processed for immunofluores-
cence microscopy. Cells were visualized with a Nikon microscope coupled
to a Bio-Rad MRC 1024 scanning confocal three-channel system.
Electron Microscopy
Conventional and whole-mount electron microscopy was performed as
described [46]. Briefly, cells grown on coverslips were fixed with 2.5%
glutaraldehyde in 0.1 M cacodylate buffer overnight and processed as
described. For whole-mount membrane preparations, the 100,000 3 g
and 10,000 3 g pellets were gently suspended in a small volume of PBS,
deposited for 20 min on formvar/carbon-coated EM grids, and processed
for EM.
Supplemental Data
Supplemental Data include five figures and can be found online at http://
www.cell.com/current-biology/supplemental/S0960-9822(09)01772-2.
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